Cargando…
Current process and future path for health economic assessment of pharmaceuticals in France
The Social Security Funding Law for 2012 introduced the Economic and Public Health Assessment Committee (Commission Evaluation Economique et de Santé Publique, or CEESP) in the Social Security Code as a specialised committee affiliated with the Haute Autorité de Santé in charge of providing recommen...
Autores principales: | Toumi, Mondher, Rémuzat, Cécile, El Hammi, Emna, Millier, Aurélie, Aballéa, Samuel, Chouaid, Christos, Falissard, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Co-Action Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802685/ https://www.ncbi.nlm.nih.gov/pubmed/27123173 http://dx.doi.org/10.3402/jmahp.v3.27902 |
Ejemplares similares
-
New drug regulations in France: what are the impacts on market access? Part 2 – impacts on market access and impacts for the pharmaceutical industry
por: Rémuzat, Cécile, et al.
Publicado: (2013) -
Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment
por: Toumi, Mondher, et al.
Publicado: (2017) -
Conflict of interest in Health Technology Assessment decisions: case law in France and impact on reimbursement decisions
por: Frybourg, Sandrine, et al.
Publicado: (2015) -
Economic impact of new active substance status on EU payers’ budgets: example of dimethyl fumarate (Tecfidera(®)) for multiple sclerosis
por: Toumi, Mondher, et al.
Publicado: (2014) -
New drug regulations in France: what are the impacts on market access? Part 1 – Overview of new drug regulations in France
por: Rémuzat, Cécile, et al.
Publicado: (2013)